AorticLab
Health Care
People
Enrico Pasquino
CEO
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Club degli InvestitoriVia a fund
Italian Angels for GrowthVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Assessment of the Safety and Effectiveness of the FLOWer Antiembolic Filter Supporting Transcatheter Aortic Valve Implantation
Abstracthttps://pubmed.ncbi.nlm.nih.gov/41709490/Background: Embolic events are life-threatening complications of transcatheter aortic valve implantation (TAVI) with clinically relevant stroke rates of 2%-4%.Aims: This study aims to evaluate the safety an
Read more
Report
AorticLab Receives FDA Approval to Initiate FLOWer Clinical Pivotal Investigation
TORINO, Italy, Oct. 2, 2025 /PRNewswire/ - AorticLab announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) for the FLOWer System pivotal clinical investigation. The FLOWer System is an inn
Read more
Report
AorticLab S.r.l. Announces Clear Victory Before the European Unified Patent Court in Litigation Brought by Emboline, Inc.
AorticLab's FLOWer embolic protection device has received full clearance following the Unified Patent Court's clear dismissal of Emboline's infringement claims regarding European Patent EP 2129425, ensuring continued patient access to its innovative techn
Read more
Report
AorticLab S.r.l. Announces Clear Victory Before the European Unified Patent Court in Litigation Brought by Emboline, Inc.
AorticLab S.r.l. today announce sits clear victory before the Court of First Instance of the Unified Patent Court (UPC), Local Division Munich, following the comprehensive dismissal of the patent infringement action filed by Emboline, Inc. concerning the
Read more
Report
AorticLab Gets FDA IDE Approval for FLOWer Clinical Pivotal Investigation
The FLOWer System is a full-body embolic protection device designed for use during transcatheter intracardiac procedures
Read more
Report
AorticLab Receives FDA Approval to Initiate FLOWer Clinical Pivotal Investigation
/PRNewswire/ -- AorticLab announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) for the...
Read more
Report
FLOWer is CE Marked
AorticLab is pleased to announce the successful achievement of CE certification for FLOWer, an innovative transcatether embolic protection device (EPD) indicated for the cerebral and systemic protection of patients undergoing transcatheter aortic valve re
Read more
Report
Protected: FLOWer - Downloads
This content is password-protected. To view it, please enter the password below. Password: L'articolo Protected: FLOWer - Downloads proviene da AorticLab.
Read more
Report
AorticLab has obtained ISO13485 certification for the design and development of its products
AorticLab has obtained ISO13485 certification for the design and development of its products. It certifies that Aorticlab has established and is maintaining a quality management system, which meets the requirements of the standard. We are proud: it means
Read more
Report
AorticLab announces First in Human cases of FLOWer, the unique embolic protection device
AorticLab, a leading innovator of cutting-edge technology solutions to treat aortic stenosis and improve patients' safety, based in Colleretto Giacosa Bioindustry Park - Turin Italy, - today announced the positive completion of the first three human proce
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Milan
Italy
HQ
AorticLab's Embolic Protection Device, FLOWer, is not available for sale in Germany